Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Featured Stories

Controversial Contraception Apps Among New Entries On EU Borderline Manual

There are six new entries in the latest version of the European Commission's manual on borderline products.

Europe Policy & Regulation Medical Device

AdvaMed Making Push For Device Tax Repeal In Lame Duck Session

The "lame duck" session of Congress before newly elected members take their seats in January may be the best shot available for the device industry to win permanent device tax repeal, lobby group AdvaMed says. The group is making a major effort to repeal the tax before the new Congress takes over.

Legislation Policy Medical Device

Market Intel: Apps for Epilepsy, Steps for Health, Meditation Guides, Mouth Labs Cross Digital Divide For Better Health

Startups at the convergence of technology and biomedical innovations showcased compelling innovations at this week's Exponential Medicine conference in San Diego. This article offers a roundup of new devices targeting a wide range of applications from neurology, cardiology, chronic diseases and wellness.

Innovation Analysis Commercial

Results Recap: VIVA Conference Yields Plethora Of Vascular Intervention Data

Results Recap is Medtech Insight's exclusive summary of clinical trial results that have been announced or published in the past week, based on information collected by Meddevicetracker. This week's edition, covering the week of Nov. 3 - Nov. 9, includes trial data presented at the VIVA (Vascular InterVentional Advances) conference in Las Vegas, Nov. 5-8 as well as data from the initial experience with Medtronic's 34-mm CoreValve Evolut R TAVR system and the PARTNER IIA trial of Edwards' Sapien XT TAVR system.

Tracking Trials Clinical Trials Innovation

How Belgium's New Local Distribution Rules Will Impact Companies Doing Business There

With new legislation imminent in Belgium on distribution rules for medical devices, how much more open is the market going to become, and what must companies be aware of? Two experts discuss.

Belgium Medical Device Europe

Latest from PR Newswire

Click here to access further medical device and diagnostics news.

Recent Tweets from Medtech Insight

Getting The Words Right: Device Documentation And Translation in Asia

Oracle Health Sciences

Although the medical device sector has seen increasing harmonization of regulations both globally and regionally, market-entry requirements in Asia still retain a significant degree of localization, particularly as they relate to product labeling and documentation.

Download the article to learn more about the challenges and potential rewards of device documentation and translation in Asia.

The article reviews:

  • New regulatory reforms and their impact
  • The role and limitations of localizing software
  • Opportunities to translate for growth

Read Article

Pharma Report Store

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now:

Shop Now

Policy & Regulation Explore this Topic

Set Alert for Policy

Special 510(k) Pilot Includes All Qualifying Submissions, FDA Says

US FDA officials clarified how devices can qualify for an ongoing special 510(k) pilot program during a Nov. 8 online seminar.

Regulation Medical Device Approvals

New Mood Among UK IVDs As Ambitious Pathology Modernization Scheme Gathers Pace

NHS England's IVD and pathology sector is undergoing a major reorganization to make it fit for the future, responsive to growing demand and more patient-friendly. The plans are helping to change mindsets locally about how IVDs and pathology services should be delivered, according to speakers at a recent summit.

In Vitro Diagnostics United Kingdom Government Payers

Complying On Time With MDR/IVDR: What Options Are Open To Those In Trouble?

Manufacturers who have not managed to transfer their certificates from a UK notified body prior to Brexit, or who have not obtained certificates under the EU Medical Device or IVD Regulations in time, can not expect to receive a sympathetic hearing from the EU Commission. In an interview with Medtech Insight, Lawyer Alison Dennis examines options for medtech firms.

Europe Medical Device

Device Week, Nov. 9, 2018 – What The US Midterms Mean For Medtech

On this week's podcast, David Filmore and Ferdous Al-Faruque discuss the results of this week's midterm elections in the US and what it could mean for the medtech sector.

Device Week Elections

NEST Test Cases Could Support Company Submissions And Determine Future Of National Device Database

Recently announced US National Evaluation System for health Technology "test cases" will be evaluated for up to a year by the NEST Coordinating Center after which collaborating device-makers may be in a better position to use real-world evidence to support new pre-market device submissions. The test cases will be measured, in part, based on their ability to identify brand-specific devices in the NEST Network Collaborators’ real-world datasets.

Clinical Trials Health Technology Assessment

3 Big Medtech Takeaways From US Midterms

The balance of power will be shifting in Washington, DC, following the Nov. 6 US midterm elections, but that probably will not mean major changes for medtech policies. Here are some key takeaways from the election for device and diagnostics companies.

Elections Legislation

US Midterms: Industry Loses Some Supporters In Congress, But Retains Many

With most of the Nov. 6 election tally completed, it’s clear there will be many new faces for the device industry to engage with in the halls of Congress, but the sector still appears to have a significant group of supporters on Capitol Hill. Also, several medtech-relevant measures were on the ballot.

Elections Legislation

Medicare Allows Use Of Hospital Outreach Lab Pay Data; Industry Applauds, But Still Sues

The clinical laboratory industry praised the US Centers for Medicare and Medicaid Services for making changes in its final Clinical Laboratory Fee Schedule rule to allow more data from hospital outreach labs to be considered in setting laboratory test pay rates. But lab advocates are still pursuing a lawsuit and pushing for legislative reforms.

Reimbursement Regulation

Quality Control & Compliance Explore this Topic

Set Alert for Quality Control

US FDA Tweaks Direct Marking Rules In UDI Enforcement Delay

FDA’s latest update to Unique Device Identification compliance deadlines says the agency won’t enforce direct marking UDI rules for some existing devices if the UDI can be determined in other ways.

Enforcement Compliance

'An Unnecessary Editorial Revision': In Letter, MDSAP Council Rails Against ISO's Push To Change 13485 Quality Standard

The chair of the Medical Device Single Audit Program (MDSAP) Regulatory Authority Council is warning of "instability" in industry if the International Organization for Standardization (ISO) Technical Management Board has its way and makes changes now to international quality systems standard ISO 13485.

International Standards

ISO Wants To Tinker With Quality Systems Standard 13485:2016. Let ISO Know What You Think By Nov. 9

Device firms don't have to conform to the latest version of ISO 13485 until March 2019, yet the International Organization for Standardization (ISO) Technical Management Board is champing at the bit to open up the quality systems standard for a rewrite. In response, ISO Technical Committee 210 has developed a survey to determine how changing the standard will affect device-makers and other stakeholders. TC210 wants to "gather opinions from the users [of ISO 13485] to justify why no immediate revision is desired, especially in light of all the regulatory changes that are coming," TC210 delegate Kim Trautman says. The survey closes Nov. 9.

International Standards

Commercial Explore this Topic

Set Alert for Commercial

Q3 Earnings Spotlight: Abiomed Shines Among Cardiology Device-Makers

Reported sales and earnings from the publicly traded cardiovascular device companies show strong performance across the sector, spurred by new approvals and clinical trials, in the quarter that ended Sept. 30. Here's a recap of results from the cardio device companies that have reported so far, including Abbott, Abiomed, and Reva.

Commercial Cardiovascular Financing

Q3 Earnings Spotlight: Ortho Firms Show Mixed Results Against US Pricing Pressure

Reported sales and earnings from the publicly traded orthopedics device companies showed mix results during the third quarter of 2018. NuVasive was the star performer in the group while, on the other end of the spectrum, Stryker continued to show strong growth across most its businesses, while Johnson & Johnson's orthopedic device revenue was near flat.</p>

Orthopedics Deals

Q3 Earnings Spotlight: Roche, Abbott, bioMérieux Lead IVD Company Results

Medtech Insight highlights Q3 2018 results from some of the leading IVD players. In this edition, we spotlight some of the big companies including Roche Diagnostics, Thermo Fisher Scientific, bioMérieux, and Becton Dickinson.

Commercial In Vitro Diagnostics

QUOTED. Nov. 8, 2018. John Damgaard.

RedMed Inc. is continuing to invest aggressively in its "software-as-a-service" offerings with the addition of MatrixCare, a provider of long-term post-acute care software. See what MatrixCare CEO John Damgaard said about it here.

Quoted Deals

Stryker To Settle Hip Implant Suits

Stryker and plaintiff attorneys are hashing out an agreement to settle thousands of lawsuits brought by patients who say they were injured by the device-maker's hip implants.

Legal Issues Commercial

Execs On The Move: Changes In Management Positions At Danaher And Johnson & Johnson

This week, a new corporate development senior VP arrives at clinical and research diagnostics firm Abcam, a VP opts out of business development post at Danaher to strategize for Agilent Tech, and a supply chain exec departs J&J.

Appointments Commercial

Medtech Money Flow: M&A And VC Deals, Oct. 29-Nov. 4, 2018

This edition of Medtech Money Flow rounds up the M&A and venture financing deals, as recorded in our M&A and VC Deal Trackers, between Oct. 29 and Nov. 4, 2018.  

M & A Financing

Clinical R&D Explore this Topic

Set Alert for Clinical R&D

Global Device Approvals, Weekly Snapshot: Parathyroid Detection, Diabetes Tech

A snapshot of global medical device approvals captured during the past week in Medtech Insight's Approvals Tracker. Two devices to help surgeons performing thyroid surgery made the list, as did several devices in the diabetes space.

Approvals Innovation Research & Development

QUOTED. Nov. 9, 2018. Pete DeComo.

When ALung Technologies was selected in 2015 by US FDA to participate in the agency's Expedited Access Pathway program for its novel Hemolung device, the firm wasn't necessarily sure what it was getting itself into. See what ALung CEO Pete DeComo said about the pathway – now called the Breakthrough Devices Program – here.

Quoted Respiratory

QUOTED. Nov. 2, 2018. Harold Safferstein.

With 25 device and diagnostics start-ups in its portfolio, the Pittsburgh Life Sciences Greenhouse aims to establish life-sciences companies in Western Pennsylvania by leveraging the area's top schools and best-in-class medical facilities. See what the Greenhouse's Harold Safferstein said about it here.

Quoted Innovation

Breathing Easy: ALung CEO Talks Novel Hemolung Device, FDA's Breakthrough Pathway, Landmark US/UK Clinical Trials

In a deep-dive sit-down interview with Medtech Insight, ALung Technologies CEO Pete DeComo dishes on US FDA's Breakthrough Devices Program and explains why his firm's novel artificial lung device, Hemolung, is worthy of traveling the expedited pathway to agency approval. DeComo also details two pivotal Hemolung clinical trials in the US and UK, and explains why Hemolung isn't marketing the device for commercial use despite being approved in 36 countries outside the US. He also talks about a future portable version of Hemolung, but noted that's not where ALung is focused right now. "Our first task is that first-generation technology – to get it to market, make it the standard-of-care, and then, if you are successful with all of that, you can do all of those wonderful other things as it relates to portability and wearability," DeComo says.

Respiratory Innovation

Life Sciences Greenhouse Plants Medtech Seeds In Pittsburgh

ALung CEO Pete DeComo says the start-up's novel Hemolung device might never have seen the light of day if it weren't for the support of the company's local community and, in particular, investment firm Pittsburgh Life Sciences Greenhouse. And ALung isn't the only Pittsburgh medtech firm the Greenhouse is aiding – there are currently 25 device and diagnostics start-ups in its portfolio.

Innovation StartUps and SMEs

Global Device Approvals, Weekly Snapshot: Neurorehab And Menopause

A snapshot of global medical device approvals captured during the past week in Medtech Insight's Approvals Tracker. Among them, a portable neuromodulation device is approved in Canada for traumatic brain injury.

Approvals Innovation

Global Device Approvals, Weekly Snapshot: HeartMate 3 Reaches New Destination

A snapshot of global medical device approvals captured during the past week in Medtech Insight's Approvals Tracker. Among the additions, Abbott's HeartMate 3 left ventricular assist device gained "destination therapy" approval from US FDA, meaning its now vetted for use in patients who are not eligible for a heart transplant.

Approvals Innovation